Abstract

Alzheimer’s disease (AD) is characterized by a progressive loss of memory and cognitive decline. However, the assessment of AD-associated functional and cognitive changes is still a big challenge. Auditory-evoked cortical potential (AECP) is an event-related potential reflecting not only neural activation in the auditory cortex (AC) but also cognitive activity in the brain. In this study, we used the subdermal needle electrodes with the same electrode setting as the auditory brainstem response (ABR) recording and recorded AECP in normal aging CBA/CaJ mice and APP/PS1 AD mice. AECP in mice usually appeared as three positive peaks, i.e., P1, P2, and P3, and three corresponding negative peaks, i.e., N1, N2, and N3. In normal aging CBA mice, the early sensory peaks P1, N1, and P2 were reduced as age increased, whereas the later cognitive peaks N2, P3, and N3 were increased or had no changes with aging. Moreover, the latency of the P1 peak was increased as age increased, although the latencies of later peaks had a significant reduction with aging. In AD mice, peak P1 was significantly reduced in comparison with wild-type (WT) littermates at young ages, proceeding AD phenotype presentation. In particular, the later cognitive peak P3 was diminished after 3 months old, different from the normal aging effect. However, the latencies of AECP peaks in AD mice generally had no significant delay or changes with aging. Finally, consistent with AECP changes, the accumulation of amyloid precursor protein (APP) at the AC was visible in AD mice as early as 2 months old. These data suggest that AECP could serve as an early, non-invasive, and objective biomarker for detecting AD and AD-related dementia (ADRD).

Highlights

  • Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by a progressive loss of memory and dementia

  • Like the Auditory-evoked cortical potential (AECP) recorded from humans, both early sensory and later cognitive waves were visible in the recorded mouse AECP, which usually presented three waveforms (Figure 1)

  • There were no significant changes in AECP in AD mice except peak N3 at 1 year old (Figure 7)

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by a progressive loss of memory and dementia. Over the last two decades, the prevalence of AD and AD-related dementia (ADRD) has been rapidly increased. This will produce a heavy economic and social burden. Detection is critical for the prevention and interventions of this common neurodegenerative disease. It is estimated that early diagnosis and interventions delaying the onset of dementia by even 1 year could decrease the worldwide prevalence of dementia by 10% (Patterson, 2018). Since the lack of early, reliable AD biomarkers, early detection of AD is still a big challenge. It lacks objective biomarkers to detect cognitive decline, which is the most common and predominant symptom of AD, at the early stage

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call